Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)

• Company Description    Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California. Number of Employees: 317

• Price / Volume Information    Yesterday's Closing Price: $17.50 Daily Weekly Monthly 20 Day Moving Average: 1,010,441 shares Shares Outstanding: 103.41 (millions) Market Capitalization: $1,809.60 (millions) Beta: 1.87 52 Week High: $22.50 52 Week Low: $8.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.61% 0.45% 12 Week 8.63% 0.42% Year To Date -7.75% -15.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1600 SIERRA POINT PKWY - BRISBANE,CA 94005 USA ph: 415-660-5320 fax: - kfortner@nurixtx.com http://www.nurixtx.com

• General Corporate Information    Officers Arthur T. Sands - President and Chief Executive Officer Julia P. Gregory - Chairman Hans van Houte - Chief Financial Officer Roy D. Baynes - Director Roger Dansey - Director Peer Information Nurix Therapeutics, Inc. (CORR.) Nurix Therapeutics, Inc. (RSPI) Nurix Therapeutics, Inc. (CGXP) Nurix Therapeutics, Inc. (BGEN) Nurix Therapeutics, Inc. (GTBP) Nurix Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67080M103 SIC: 2834 Fiscal Year Fiscal Year End: November Last Reported Quarter: 02/01/26 Next Expected EPS Date: 07/08/26 Share - Related Items Shares Outstanding: 103.41 Most Recent Split Date: (:1) Beta: 1.87 Market Capitalization: $1,809.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.94 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/08/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.76 Price/Cash Flow: - Price / Sales: 25.21 EPS Growth vs. Year Ago Period: -17.91% vs. Previous Quarter: 3.66% Sales Growth vs. Year Ago Period: -66.12% vs. Previous Quarter: -53.95% ROE 02/28/26 - -64.21 11/30/25 - -57.51 08/31/25 - -53.57 ROA 02/28/26 - -48.44 11/30/25 - -43.76 08/31/25 - -40.82 Current Ratio 02/28/26 - 6.01 11/30/25 - 7.02 08/31/25 - 5.35 Quick Ratio 02/28/26 - 6.01 11/30/25 - 7.02 08/31/25 - 5.35 Operating Margin 02/28/26 - -411.37 11/30/25 - -314.90 08/31/25 - -292.50 Net Margin 02/28/26 - -411.37 11/30/25 - -314.90 08/31/25 - -292.50 Pre-Tax Margin 02/28/26 - -410.32 11/30/25 - -314.00 08/31/25 - -291.58 Book Value 02/28/26 - 4.65 11/30/25 - 5.29 08/31/25 - 4.87 Inventory Turnover 02/28/26 - - 11/30/25 - - 08/31/25 - - Debt-to-Equity 02/28/26 - 0.00 11/30/25 - 0.00 08/31/25 - 0.00 Debt-to-Capital 02/28/26 - 0.00 11/30/25 - 0.00 08/31/25 - 0.00

Powered by Zacks Investment Research ©